We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Mutation Causes Lethal Condition in Infants

By LabMedica International staff writers
Posted on 05 Aug 2015
Protein losing enteropathy (PLE) is a condition of the gastrointestinal tract that results in loss of protein from the body, and often leads to severe abdominal swelling, malnutrition and early death in affected infants.

Whole-exome sequencing has been used to identify a nonsense mutation in the plasmalemma vesicle-associated protein gene that results in a distinct severe form of PLE characterized by hyperproteinemia, hypoalbuminemia, and hypertriglyceridemia.

Scientists at the Hospital for Sick Children (Toronto, ON, Canada) obtained samples from a patient with the PLVAP p.Arg358* mutation on two occasions during endoscopic investigation for severe PLE. More...
Control samples from the duodenum or colon were obtained from patients who were undergoing evaluation of gastrointestinal symptoms, among whom the endoscopic, histologic, and follow-up clinical impressions were normal.

Whole-exome sequencing was performed and the exome library preparation was performed using the Ion Torrent AmpliSeq RDY Exome Kit (Life Technologies; Carlsbad, CA, USA) and DNA quantified by Qubit DNA HS or BR assay (Life Technologies). The library was purified with Agencourt Ampure XT beads (Agencourt Bioscience; Beverly, MA, USA). Libraries were quantified by quantitative polymerase chain reaction (PCR) and sequenced on an Ion Torrent Proton Sequencer using a PI chip V2. The investigators used a variety of techniques for their study including flow cytometry read on a FACSCalibur (BD Biosciences; San Jose, CA, USA), confocal microscopy, histology and immunofluorescence.

The defect caused by mutations in PLVAP was due to increased leakage from small blood vessels rather than active loss from the cells lining the intestines. This finding is different from most cases of enteropathy, including the Microvillus Inclusion Disease and Congenital Tufting Enteropathy, which affect young children. In these latter conditions, genetic abnormalities cause cellular abnormalities primarily affecting intestinal epithelial tissue structure and function.

Abdul Elkadri, the lead study author, said, “These findings come at a critical time in medical science; the recent promise of gene therapy may make targeted correction of PLVAP mutations possible. In the meantime, we can use these findings to develop more rapid diagnostic strategies to screen infants for this genetic mutation and prevent severe complications at an early stage of the disease.” The study was published in the July 2015 issue of the journal Cellular and Molecular Gastroenterology and Hepatology.

Related Links:

Hospital for Sick Children
Life Technologies
Agencourt Bioscience




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.